Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

Summary

A dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanomas.

Timeline

Start

2008-06

Primary completion

2009-12

Completion

2010-05

Outcome

Met primary endpoint

release “MKC1106-MT and MKC1106-PP met the primary end-points of both trials” mannkindcorp.com ↗

Drugs

Indications